Ann: Novogen submits IND Application to the FDA for Cantrixil-NRT.AX, page-85

@rusty02 , so sad for your loss!!...this was from last year...wtf happened???

http://hotcopper.com.au/threads/ann-anisina-on-track-to-enter-clinic-in-2016.2540331/#.V66aNE0QaUk

From 24th June 2015 announcement - ANISINA ON TRACK TO ENTER CLINIC IN 2016:

"Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said, "This result clears the way for Anisina to enter the clinic. The potent effect observed here of the drug on a cancer as difficult to treat as malignant melanoma, combined with the lack of any obvious toxicity of the drug, justifies our earlier speculation that destroying a cancer cell’s microfilaments would yield an equivalent therapeutic benefit to destroying the microtubules, but without the toxicity of the latter."
"Large-scale manufacture of the compound now is underway with a target of being in a first-in-man study in 2Q16," Stehn added."

WHAT happened to the large scale manufacturing and our approach of outsourcing the drug dev to fastrack these IND applications???

@rusty said: "Anisina

Approval of "Large scale manufacturing"
2nd Quarter clincal trials to commence.
Both intra and oral proved effective
Anisina; ability to improve taxanes and vinca alkaloids side effects.
No toicity.

In the time that I have been researching NRT, management have constantly de-risked the company moving forward. This ANN has just de-risked NRT, yet again, from an investors point of view where it will seem possible/probable, now, for the clinical trial next year to be conclusive and to fast track Anisina into stage 2.
GL all
cheers"

I think this drug will provide a baseline for NRT and just hope our board are driving to bring this into the clinic this year!!! From the above it should be possible...